Marc is Chief Business Officer of Tectonic Therapeutic, with 15+ years of experience in Biopharma, Consulting, Finance, and Science to Tectonic. Previously, Marc was SVP Business Development and US Operations at Fusion Pharma where his transactions, amongst others, included the company’s Series B, IPO, and an expansive partnership with AstraZeneca. Prior to Fusion, Marc was Head of US Pharma Business Development at Bayer, held roles in Business Development and Alliance Management at Eisai, Strategy Consulting at Leerink Swann (now Guidehouse), and Healthcare Investment Banking at RBS. Marc has led deals across various therapeutic areas; from early technologies to development-stage and to commercialized assets; buy-side, sell-side, partnerships, and financings; and a mix of deal/financing structures. He holds a PhD in Biochemistry and Molecular Pharmacology from Harvard and a BS in Biology from Cornell.